Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The study is a randomized, proof of concept study. 30 patients aged 18 and over with HS will
be included in this single center, randomized, double-blind, parallel-group study. Dosage of
deucravacitinib will be given according to the investigational regimen as follows: 6 mg po
bid for 16 weeks. The study compromises a 4-week screening period, a 16-week study period,
and a 4-week follow-up period. The follow-up period consists of a follow-up phone call 4
weeks after the last study drug dose.